Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Court Win Keeps Sandoz' Biosimilar Rituximab Off Australian Market For A Year

Executive Summary

A decision by an Australian court to prevent Sandoz from launching its biosimilar rituximab in Australia until August 2019 means a continued monopoly for Roche and lost sales for Sandoz, while the healthcare system misses out on significant potential savings.

You may also be interested in...



Australian ‘Uptake Drivers’ For Boosting Biosimilar Prescribing Start With Etanercept

Biosimilars are being given a boost in Australia through the use of “uptake drivers” to encourage doctors to prescribe a biosimilars in preference to the reference product. The first product involved is etanercept.

UK Industry Gets More Time To Adapt To Post-Brexit Import Rules

The BioIndustry Association has welcomed a decision to delay the deadline for compliance with new regulations on the classification of imported materials used in drug production, but says the border rules are still not proportionate for life science products.

Industry Calls On G20 To Boost Regulatory Harmonization & Tackle AMR

Robust regulatory systems with effective approval pathways and surveillance mechanisms to ensure continuity in clinical research, manufacturing and supply are needed to prepare for current and future health threats, says industry.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB002403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel